Providers

Latest News

While both are anti-CD20 antibodies, obinutuzumab is a glycoengineered type II CD20 antibody, and rituximab is a type I CD20 antibody, meaning a different mode of binding to CD20 antigen. | Image credit: Eleni - stock.adobe.com

Long-Term Data Show Favorable Survival Outcomes With G-Clb in Treatment-Naive CLL

By AJMC Contributor

May 1st 2025

Participants in the CLL11 trial and a smaller group of patients followed after study completion showed improved overall survival with obinutuzumab and chlorambucil (G-Clb) compared with chemotherapy plus rituximab or chemotherapy alone for chronic lymphocytic leukemia (CLL).

Liver cancer - Sebastian Kaulitzki - stock.adobe.com.jpg

Elevated HLA-G Seen in HCC Driven by Viral Infections, Fatty Liver

By AJMC Contributor

May 1st 2025

The results offer some of the first glimpses into real-world findings of the JAK inhibitor momelotinib, which was approved in 2023. | Image credit: mdaros - stock.adobe.com

Real-World Findings Confirm Clinical Data on Momelotinib in MF With Anemia

By AJMC Contributor

May 1st 2025

Fillingoutaformforaclinicaltrial | Image Credit: © KayExam/peopleimages.com-stock.adobe.com

Keep Patients at the Center of Clinical Research

By Maggie L. Shaw

April 30th 2025

Patients with LR-MDS, particularly those with the highest rates of infection-related deaths, would benefit from close monitoring for infections. | Image credit: Saiful52 - stock.adobe.com

Infection Linked With Nearly a Quarter of Deaths in Lower-Risk MDS

By Rose McNulty

April 30th 2025

...

107 108 109 110 111

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions